skip to the content

Clinical Trials

Schizophrenia - Relapse Prevention Study

Relapse Prevention: Long-Acting Atypical Antipsychotics (GAC 0174)

Protocol ID

05.04.063

Protocol Description

The purpose of this study is to determine: 1) if patients with schizophrenia and schizoaffective disorder who have had a worsening of symptoms in the past 12 months maintain better control of the symptoms of their illness by taking an antipsychotic medication, risperidone microspheres (Risperdal Consta®), by injection or by taking any of the other available “atypical” (second generation) antipsychotics by mouth.2) which medication is most effective for preventing relapse and 3) if there are differences in a person’s social, educational, and work involvement that are related to the type of medication being taken.

Eligibility Criteria

Patients diagnosed with schizophrenia or schizoaffective disorder

Primary Investigator(s)

  • Alan Mendelowitz, MD

Contact Information

Susan Ray, MS
(718) 470-8442
sray@lij.edu

Last Update

April 12, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Mental Health:
top
top